Significant operating cost and workforce reductions estimated to lower operational expenses by approximately $18 million in 2018
Recent Press Releases
VANCOUVER, British Columbia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Michael Price as senior vice president and chief financial officer (CFO), effective December 4, 2017. Gregory Perry has resigned as CFO of Novelion to pursue other opportunities, and will remain with the Company until December 31, 2017 to enable an effective transition.
- Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer
- Defined Clinical Development Plan for Zuretinol Following Positive FDA Meeting
- Company Reiterates FY 2017 Total Net Revenues Guidance
Between $155 and $165 million
- Conference call to be held today at 8:30 a.m. ET